Hypothyroidism in HIV-Infected Patients Who Have or Have Not Received HAART [2]

Clinical Infectious Diseases

Volumn 38, Issue 4, 2004, Pages 596-597

  Quirino, T ^a,b   Bongiovanni, M ^a   Ricci, E ^c   Chebat, E ^b   Carradori, S ^d   Martinelli, C ^e   Valsecchi, L ^a   Landonio, S ^a   Bini, T ^a  

^a Ist Ric Farmacologiche Mario Negri ^*  (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^d S ANNA HOSPITAL   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; RECOMBINANT INTERFERON; THYROTROPIN; THYROXINE;

ADULT; CONTROLLED STUDY; FEMALE; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOTHYROIDISM; LETTER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; HIV INFECTIONS; HUMANS; HYPOTHYROIDISM; MALE; PREVALENCE; RISK FACTORS;

EID: 1342322677     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/381442     Document Type: Letter

References (4)

1. Beltran S, Lescure FX, Desailloud R, et al. Increased prevalence of hypothyroidism among human immunodeficiency virus-infected patients: a need for screening. Clin Infect Dis 2003; 37:579-83.
2. Calza L, Manfredi R, Chiodo F. Subclinical hypothyroidism in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 31:361-3.
3. Grappin M, Piroth L, Verges B, et al. Increased prevalence of subclinical hypothyroidism in HIV patients treated with highly active anti-retroviral therapy. AIDS 2000; 14:1070-2.
4. Hak AE, Pols HA, Visser TJ, et al. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med 2000; 132:270-8.